Peripheral Neuropathies
Carbon disulfide neuropathy
Jun. 11, 2026
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Autonomic neuropathy treatment …
- Updated 11.10.2025
- Released 09.19.2003
- Expires For CME 11.10.2028
Autonomic neuropathy: treatment
Introduction
Overview
Autonomic neuropathy has numerous causes, some of them common, such as diabetic autonomic neuropathy, and others rare, such as Fabry disease, but all can produce disabling symptoms. Autonomic neuropathy can affect the sympathetic, parasympathetic, and enteric branches of the autonomic nervous system to variable degrees, causing dysfunction of different organs such as the heart, intestinal tract, and urinary bladder. In this article, the authors review the available symptomatic treatments of these dysfunctions, focusing mainly on orthostatic hypotension, postural orthostatic tachycardia syndrome (POTS), gastroparesis, bladder hypomotility, and erectile dysfunction. Emerging treatment for amyloidosis may affect the outcome of the associated autonomic neuropathy. This will be reviewed. A brief physiological and pathophysiological review and a discussion of available treatments are included for each disease discussed.
Key points
|
• Although autonomic neuropathy can be disabling, the patient's symptoms and quality of life can be improved efficiently. | |
|
• In general practice, postural orthostatic tachycardia syndrome (POTS) can be easily overlooked. | |
|
• New promising treatments are available for orthostatic hypotension, postural orthostatic tachycardia syndrome, and gastroparesis. |
Orthostatic hypotension
Pharmacotherapy of orthostatic hypotension
Physiology and pathophysiology. Orthostatic hypotension is the most incapacitating symptom of autonomic failure. Severely afflicted patients are unable to leave the supine position without experiencing symptoms of presyncope or losing consciousness. Baroreceptor reflexes maintain hemodynamic stability in response to postural change. These reflexes depend on blood pressure information from the aortic arch and the carotid sinus, which enters the brain in the IX and X cranial nerves. The hallmark of neurogenic orthostatic hypotension is the failure to release norepinephrine appropriately on standing. Patients with neurogenic orthostatic hypotension due to pure autonomic failure or an autonomic peripheral neuropathy typically have lower resting norepinephrine levels, due to degeneration of the post-ganglionic neurons, although intersubject variability limits the use of this measure as a diagnostic test (17).
Preclinical studies suggest that alpha7 nicotinic receptors (alpha7-nAChR) play a role in modulating autonomic ganglia and the cholinergic anti-inflammatory pathway (03).
Treatment of orthostatic hypotension
Nonpharmacological measures. Patient education is the cornerstone of the management of orthostatic hypotension. Patients with orthostatic hypotension should move from a supine to standing position in gradual stages particularly in the morning, when orthostatic tolerance is lowest (43). A number of physical maneuvers can help maintain blood pressure during daily activities such as leg crossing, stooping and squatting (58). The excessive natriuresis and reduction in central blood volume can be attenuated or minimized by increasing sodium intake with high-sodium containing foods or salt tablets. Raising the head of the bed 10 degrees to 20 degrees activates the renin-angiotensin-aldosterone system and decreases the nocturnal diuresis (35).
The use of custom fitted elastic stockings permit the application of a graded pressure to the lower extremity and abdomen. It is essential that such stockings extend to the waist as most peripheral pooling occurs in the splanchnic circulation. These stockings are poorly tolerated by many patients, particularly those with painful peripheral neuropathies or motor dysfunction.
Pharmacological measures. Numerous agents from diverse pharmacological groups have been implemented in the treatment of orthostatic hypotension (see Table I). The therapeutic goal is merely to ameliorate all symptoms while avoiding side effects. There is rarely the need to restore normotension.
Table 1. Pharmacotherapy of Orthostatic Hypotension
|
Mineralocorticoids | |
|
9 alpha-fludrocortisone | |
|
Sympathomimetic agents | |
|
Midodrine | |
|
Acetylcholinesterase inhibitors | |
|
Pyridostigmine | |
|
Nonspecific pressor agents | |
|
Ergot derivatives | |
|
Beta-adrenergic blocking agents | |
|
Propranolol | |
|
Prostaglandin synthetase inhibitors | |
|
Indomethacin | |
|
Dopamine blocking agents | |
|
Metoclopramide | |
|
V1 and V2 receptor agonists | |
|
Desmopressin acetate (DDAVP) | |
Agents to increase central blood volume
9-alpha-fluorohydrocortisone. 9-alpha-fluorohydrocortisone (fludrocortisone acetate), a synthetic mineralocorticoid, can be used to supplement the increase in dietary fluids and salt (19). This agent has a long duration of action and is well-tolerated by most patients. Fludrocortisone increases the blood volume and may enhance the sensitivity of blood vessels to circulating catecholamines (19; 10). Treatment is initiated with a 0.1 mg tablet daily. Little benefit is obtained by increasing beyond 0.3 to 0.5 mg. Treatment may be limited by supine hypertension due to an increase in the peripheral vascular resistance (07). Other side effects include ankle edema, hypokalemia and rarely congestive heart failure. Potassium supplementation is usually required, particularly when higher doses are used. Adequate salt and water intake are also important and may obviate the need for this agent in milder cases.
Agents to increase peripheral vascular resistance
Vasopressin analogues. The synthetic vasopressin analogue desmopressin acetate (DDAVP) may also be used to enhance fluid retention in patients with orthostatic hypotension. DDAVP, which can be taken as a nasal spray (10 to 40 mcg) or orally (100 to 800 mcg), may prevent the nocturia and weight loss, and it reduces the morning postural fall in blood pressure in patients with autonomic failure. Fluid and electrolyte status should be carefully monitored during therapy to avoid hyponatremia (36). Lower doses (5 mcg intranasally) may be clinically effective and avoid these side effects (52).
Sympathomimetic agents. A direct or indirect sympathomimetic agent may be used in conjunction with central blood volume supplementation should the patient remain symptomatic (24). The available alpha-1 adrenoreceptor agonists include those with direct and indirect effects (eg, ephedrine and pseudoephedrine), those with direct effects (midodrine, phenylephrine) and those with only indirect effects (eg, methylphenidate and dextroamphetamine sulphate). Ephedrine (25 to 50 mg, three times a day) and pseudoephedrine (30 to 60 mg, three times a day) are now the most frequently prescribed indirectly acting agents.
The peripheral selective alpha-agonist, midodrine, is approved by the FDA for the treatment of orthostatic hypotension. The pressor effect of midodrine is due to both arterial and venous constriction. The efficacy of this agent has been demonstrated in open-label and double-blind studies (15; 32). Midodrine, the prodrug is activated to deglymidodrine the active alpha-receptor agonist. Patient sensitivity to this agent varies, and the dose should be titrated from 2.5 to 10 mg three or four times a day (66). Potential side effects of this agent include pilomotor reactions, pruritus, supine hypertension, gastrointestinal complaints, and urinary retention. This agent does not cross the blood brain barrier and central nervous system side effects occur infrequently (40; 38). There are few head-to-head comparisons of the alpha-adrenoreceptor agonists. In a small clinical trial midodrine (mean dose 8.4 mg, three times daily) improved standing blood pressure and orthostatic tolerance more than ephedrine (22.3 mg, three times daily) (13).
Atomoxetine, a norepinephrine reuptake inhibitor, has been studied as a therapy for orthostatic hypotension. One study looked at the short term-effect of this medication (up to 60 minutes) and showed increase in seated and standing systolic blood pressure in patients with central (but not peripheral) autonomic failure. Of note, the mean seated pressure was in the hypertensive range (53). In comparison to the short-term effect of midodrine, atomoxetine was found to be superior in producing greater pressor response in upright position and improving symptoms (47). In a comparison study of 50 patients with orthostatic hypotension secondary to different etiologies (eight patients with diabetic autonomic neuropathy, five with nondiabetic autonomic neuropathy, eight with multiple system atrophy, and 29 patients with unspecified orthostatic hypotension), patients were randomized to receive either atomoxetine or midodrine (04). Atomoxetine for one month (18 mg daily) was found to be as effective as midodrine in improving the orthostatic blood pressure drop and was found to be superior in alleviating the symptoms as evaluated by a self-reported questionnaire. In another study of 12 patients with severe autonomic failure (five with pure autonomic failure, three with probable multiple system atrophy, two with Parkinson disease, one patient with amyloidosis, and one with autonomic failure of unknown etiology), the combination of atomoxetine and pyridostigmine helped decrease the orthostatic symptoms burden after a single dose of each drug, whereas pyridostigmine alone did not, and atomoxetine did not reach statistical significance in improving the symptoms on its own (42).
Droxidopa (L-threo dihydroxyphenylserine, L-DOPS), a synthetic amino acid precursor of the neurotransmitter and hormone norepinephrine, has been approved for use in Japan since 1989; the United States FDA approved this medication in February 2014 for treatment of neurogenic orthostatic hypotension. Droxidopa was found to be well tolerated in long-term use in a study of 350 patients who received 100 to 600 mg three times daily of droxidopa for an average of 363 days. Most reported adverse reactions, including cardiovascular ones, were not attributed to the medication (23).
Cholinesterase inhibitors. Pyridostigmine improves standing blood pressure in patients with orthostatic hypotension without aggravating supine hypertension (55). Pyridostigmine (60 mg three times daily) can be used with or without low dose of midodrine (5 mg), which could provide more potent and more sustained pressor response. The greatest effect is on diastolic blood pressure, suggesting that the improvement is due to increased total peripheral resistance. The proposed mechanism is that by enhancing ganglionic transmission, pyridostigmine augments baroreflex-mediated increases in systemic resistance proportional to the magnitude of orthostatic stress.
Agents to increase red cell mass
Erythropoietin. Erythropoietin increases standing blood pressure and improves orthostatic tolerance in patients with orthostatic hypotension (21; 44). This agent corrects the normochromic normocytic anemia that frequently accompanies autonomic failure. Recombinant human erythropoietin is administered subcutaneously or intravenously at doses between 25 U to 75 U per kilogram three times a week until a hematocrit that approaches normal is attained. Lower maintenance doses (approximately 25U per kilogram three times a week) may then be used. Iron supplementation is usually required, particularly during the period when the hematocrit is increasing. The mechanism of action for the pressor effect of this agent is unresolved (21). However, concerns of excessive supine hypertension and increased cardiovascular and cerebrovascular disease risk have reduced the use of this agent for neurogenic orthostatic hypotension.
Other agents. A list of other agents that have been used in the treatment of orthostatic hypotension is present in Table 1.
Postural orthostatic tachycardia syndrome (POTS). POTS is defined as the development of orthostatic symptoms associated with a heart rate increment of 30 or greater, usually to 120 bpm or greater without orthostatic hypotension.
Pathophysiologic mechanisms include peripheral denervation, hypovolemia, venous pooling, beta receptor supersensitivity, psychological mechanisms, and presumed impairment of brain stem regulation. These different mechanisms result in different types of POTS. The most common types are neuropathic POTS, hyperadrenergic POTS, and POTS with deconditioning. Hyperadrenergic POTS shows BP increase on standing and elevated norepinephrine level, which differs from neuropathic POTS that lacks these features. Patients can benefit from pathophysiologically based regimen of management (33). All patients with POTS require a high salt diet, copious fluids, and postural training. Many require beta receptor antagonists in small doses and low-dose vasoconstrictors. In a study by Lai and colleagues, treatment with both midodrine and beta blockers was associated with overall improvement in POTS patients' general health (30). Midodrine is probably an effective treatment for neuropathic but not for hyperadrenergic POTS (50). A study conducted at Vanderbilt University showed that low-dose oral propranolol significantly attenuated tachycardia and improved symptoms in POTS (45). Higher-dose propranolol did not further improve, and may worsen, symptoms. A previous study from the same university showed that acute acetylcholinesterase inhibition (using pyridostigmine) significantly attenuated tachycardia in POTS (46). There was also an improvement in symptom burden with this therapy. Octreotide was also studied as a treatment for POTS and orthostatic intolerance. In a comparison of midodrine and octreotide, both of them suppressed tachycardia in POTS and improved standing times in orthostatic intolerance (20). The two drugs had similar potencies; combination therapy was not significantly better than monotherapy.
Octreotide might be effective in refractory cases of POTS and orthostatic hypotension that do not respond to other medications. In a study performed by Kanjwal and colleagues, a small group of patients (12) with refractory orthostatic intolerance who did not respond to any other therapeutic modality were started on octreotide (26). Six out of twelve patients reported symptomatic improvement. Standing heart rate was significantly reduced whereas systolic blood pressure was increased in five patients. (Blood pressure and heart rate data before and after octreotide administration were available from these five patients only). A randomized controlled study is needed to verify these findings.
Coffin and colleagues found that acute use of desmopressin significantly attenuated tachycardia and improved symptoms in POTS (08). Safety with chronic use (with hyponatremia being the main concern) needs further evaluation.
The treatment of POTS after COVID-19 infection or vaccination is mainly focused on lifestyle modifications, such as increased fluid and salt intake, exercise, and graduated compression stockings. Pharmacotherapy, such as beta-blockers, fludrocortisone, midodrine, and ivabradine, may also be used in selected cases (11). Further research is needed to understand the underlying mechanisms, risk factors, and optimal treatment strategies for this complication (41).
Bowel hypomotility
Treatment of bowel hypomotility
Physiology and pathophysiology. The autonomic control of the gastrointestinal tract is mediated by the extrinsic parasympathetic and sympathetic nervous systems and the intrinsic enteric nervous system. The post-synaptic cholinergic neurons provide excitatory input to the gastrointestinal tract whereas the sympathetic nervous system provides inhibitory input to the gastrointestinal tract (18; 29; 16). The enteric nervous system is comprised of a myenteric plexus located between the inner-circular and outer-longitudinal smooth muscle layers (Auerbach plexus) and a submucosal plexus (Meissner plexus). Numerous intrinsic enteric neurons have been identified, and any individual neuron may contain multiple neuropeptides. Even in the absence of extrinsic autonomic nervous system influences, the enteric nervous system governs basic gut functions (18; 29; 16).
The degeneration of both extrinsic and intrinsic autonomic neurons in patients with autonomic failure results in symptoms of gastrointestinal dysfunction that involve both the upper and the lower gastrointestinal tract (06; 62). The symptoms of upper gastrointestinal autonomic dysfunction are exemplified by the features of gastroparesis diabeticorum: abdominal bloating, post-prandial fullness, early satiety, nausea and vomiting occur commonly in diabetic patients. Constipation, abdominal fullness and fecal incontinence are the hallmarks of lower gastrointestinal tract dysfunction. The constipation may alternate with diarrhea, particularly in patients with diabetic autonomic neuropathy.
Pharmacotherapy of diabetic gastroparesis. In these patients, glucose control should be optimized as hyperglycemia may delay gastric emptying. The prokinetic agents, metoclopramide, erythromycin, domperidone and cisapride are the primary pharmacological agents used to treat this disorder. These agents enhance gastric emptying and improve the symptoms of gastroparesis.
The benzamide, metoclopramide (5 to 20 mg orally, 30 minutes before meals and at bedtime), accelerates gastric emptying and also has a central antiemetic action. The prokinetic effects are due to augmented release of acetylcholine from enteric cholinergic neurons (due to activation of 5-HT4 receptors) and dopamine (D2) receptor antagonism. The central antiemetic effects of metoclopramide are mediated by dopamine (D2) receptor and serotonin (5-HT3) receptor antagonism in the area postrema of the periaqueductal gray. Patients maintained in the long term on metoclopramide may be at risk for the development of tardive dyskinesia and other dopamine-antagonist-related side effects (05; 22; 57).
Domperidone is a D2 receptor antagonist that does not cross the blood-brain barrier. Efficacy in the treatment of gastroparesis has been demonstrated in several clinical trials. Although this drug has no central anti-dopaminergic effects, some central antiemetic effects may be due to activity in the area postrema. This agent is not available in the United States (05; 22; 57).
A review of 28 studies assessing the adverse events experienced with domperidone and metoclopramide showed that cardiovascular, neurologic, and endocrine adverse events were commonly observed (varying from 1% to greater 50%) (25). Restlessness and extrapyramidal adverse events occurred in 15% of patients treated with metoclopramide, whereas clinically important adverse events, such as QT prolongation, were reported in 5% of patients treated with domperidone. Therefore, there is a need for agents with better side effects and safety profile. Velusetrag, a highly potent and highly selective 5-HT4 agonist with a minimal affinity for other receptors, including other 5-HT receptors and dopamine receptors (predictive to have less off-target effects), was studied at doses of 5, 15, and 30 mg for 12 weeks (01). The treatment was generally well tolerated. Gastric emptying studied by scintigraphy showed improvement with treatment, but only the low dose of 5 mg showed short-term improvement in gastroparesis symptoms. This lack of correlation highlights the need for additional studies on velusetrag.
Erythromycin, administered both orally (250 mg, three times daily) and intravenously (3 mg/kg every 8 hours), improves gastric emptying and gastroparetic symptoms. This agent and related macrolide compounds exhibit strong in vitro affinity for motilin receptors and have agonist properties that mimic the prokinetic action of exogenous motilin, a gastrointestinal polypeptide (05; 22; 57).
Studies have focused on the promising use of ghrelin agonist (intravenous medication) in severe gastroparesis. It substantially reduces the frequency and severity of nausea and vomiting as well as overall gastroparesis symptoms, supporting further investigation of its use in the management of severe gastroparesis (65). Oral ghrelin agonist resulted in reduction of gastroparesis symptoms whereas subcutaneous agonist showed symptomatic improvement and accelerated gastric emptying at 1 and 2 hours, but neither medication showed significant change in the primary endpoint (gastric half-emptying time) (12; 54).
Studies of gastric pacing have not produced consistent results in patients with diabetic gastroparesis (05; 22; 57).
Gastric electrical stimulation. Gastric electrical stimulation utilizes series of electric pulses to stimulate the stomach to contract. These pulses are produced by an implantable device, which consists of electrodes sutured to the muscular layer of the stomach and connected to a pulse generator implanted in a subcutaneous pocket in the abdominal wall. Gastric electrical stimulation can lessen symptoms of gastroparesis and frequency of vomiting within 6 weeks (39). This therapy is a low morbidity treatment option that may help patients whose symptoms fail to improve with medical therapy. A clinical trial showed that gastric electrical stimulation improved gastroparetic symptoms at 6 months with a sustained response at 12 months. Gastric emptying at 2 hours was also significantly reduced (02). Another study showed that gastric electrical stimulation therapy significantly improved subjective and objective parameters in patients with severe gastroparesis; efficacy was sustained for up to 10 years and was accompanied by good safety and tolerance profiles (37).
Furthermore, gastric electrical stimulation was found to improve basal unstimulated gastric frequency (on electrogastrogram) to near normal after few years of use. This may indicate gastric remodeling with long-term use of gastric electrical stimulation (61).
Gastric per-oral endoscopic myotomy (endoscopic pyloromyotomy). Gastric per-oral endoscopic myotomy has been utilized in refractory gastroparesis with promising results. In one study, 30 patients underwent this procedure, and the clinical response was seen in 86% of patients. Gastric emptying scan was repeated in 17 patients after the procedure, and it normalized or improved in 14 patients (27).
Pharmacotherapy of bowel hypomotility. An increase in dietary fiber (up to 25 g/day), with water (10 ounces four times per day) and exercise is the first line of therapy for most patients. The use of psyllium (up to 30 g/day) or methylcellulose (up to 6 g/day) with a concomitant increase in fluid intake will further increase stool bulk. These agents and fiber should be increased gradually and concomitantly with an increase in fluid ingestion.
Stool softeners (eg, docusate sodium 100 to 500 mg/day) or lubricants (eg, mineral oil) together with an osmotic laxative (eg, lactulose 15 to 60 ml/day) may be used if the above measures are ineffective. Glycerin suppositories or sodium phosphate enemas stimulate evacuation by promoting fluid retention in the rectum (see Table 2).
Table 2. Pharmacotherapy of Bowel Hypomotility
|
Bulk agents | |||
|
• Bran | |||
|
Laxatives and cathartics | |||
|
• Osmotic laxatives and cathartics | |||
|
- Lactulose | |||
|
• Contact cathartics | |||
|
- Diphenylmethane derivatives | |||
|
Phenolphthalein | |||
|
- Anthraquinone derivatives | |||
|
Senna | |||
|
- Ricinoleic acid (castor oil) | |||
|
Stool softeners and lubricants | |||
|
• Mineral oil | |||
|
Prokinetic agents | |||
|
• Metoclopramide | |||
|
- Bethanechol | |||
|
• Opioid antagonists | |||
The contact cathartics such as the diphenylmethane derivatives (phenolphthalein and bisacodyl), the anthraquinone (senna and cascara) should be used sparingly, although the use of these agents often cannot be avoided in patients with constipation due to severe autonomic failure. Extensive use of these agents may damage the myenteric plexus producing cathartic bowel. Other agents that may be helpful include the synthetic prostaglandin E1 analog, misoprostol, the neurotrophin, NT3, and the 5-HT4 partial agonist, tegaserod (48; 62).
Bladder hypomotility
Treatment of bladder hypomotility
Physiology and pathophysiology. The bladder wall is comprised of three layers of interdigitating smooth muscle and serves as a receptacle for the storage and appropriate evacuation of urine. This smooth muscle, the detrusor muscle, forms the internal sphincter at the junction of the bladder neck and urethra whereas the external sphincter is formed from the striated muscle of the urogenital diaphragm and is a true anatomical sphincter. The bladder has parasympathetic, sympathetic, and somatic innervation (14).
Pharmacotherapy of bladder hypomotility. Initial therapy should emphasize timed voiding schedules with bladder contractions enhanced by a Valsalva maneuver and Crede maneuver. Clean intermittent self-catheterization, however, is the primary therapy for impaired or absent detrusor muscle activity. The interval between catheterizations should be designed to maintain a residual volume of less than 100 cc and avoid incontinence. The majority of patients performing self-catheterization will develop bacteruria; however, antibiotic therapy is only necessary if symptomatic urinary tract infections occur (14).
Pharmacotherapy has a limited role in the treatment of detrusor areflexia. Stimulation of muscarinic, postganglionic receptors results in enhanced bladder contractility. Bethanechol chloride is a parasympathomimetic drug with relatively selective action at the urinary bladder. This agent may be effective in chronic states of detrusor atony or hypotonicity (60). Typical oral doses range from 25 to 100 mg four times daily (60).
Erectile dysfunction
Treatment of erectile dysfunction
Physiology and pathophysiology. Cholinergic and noncholinergic nonadrenergic neurotransmitters mediate erectile function by relaxing the arterial and trabecular smooth muscle of the corpus cavernosum, thereby increasing the flow of blood into the sinusoidal spaces of the corpora cavernosum. The resulting corporeal engorgement produces veno-occlusion by compression of the subtunical emissary veins against the tunica albuginea (34). Nitric oxide is an important mediator of noncholinergic nonadrenergic corpus cavernosum relaxation. In vivo studies of isolated corpus cavernosum tissue from diabetic men have demonstrated functional impairment in autonomic and endothelial dependent nitridergic relaxation of corpus cavernosum smooth muscle (51).
Pharmacotherapy of erectile dysfunction. Oral therapy with sildenafil, the selective phosphodiesterase 5 inhibitor, is now the first line therapy for male erectile dysfunction (49). Not all patients with autonomic failure respond to this medication. The medication is contraindicated in patients treated with nitrates and agents that compete with or inhibit the cytochrome P-450 system. Angina, hypertension requiring treatment with multiple medications, and congestive heart failure are also contraindications (28). Some phosphodiesterase 5 inhibitors, ie, vardenafil, tadalafil, and avanafil, are approved by the United States FDA for the treatment of erectile dysfunction. The dopamine (D1- and D2-receptor) agonist, apomorphine, administered sublingually is approved for the treatment of erectile dysfunction in the European Union. Apomorphine is approved by the United States FDA for the treatment of Parkinson disease.
Other pharmacological therapies include the injection of vasoactive substances such as papaverine, phentolamine and prostaglandin E1 into the corpus cavernosum, and transurethral delivery of vasoactive agents (59; 68; 56; 67; 31). The use of mechanical devices such as the vacuum erection device or constricting rings (63) and penile prosthetic implants may be used if these therapies fail or are not tolerated by the patient.
Amyloidosis
Treatment of amyloidosis
Eplontersen, a TTR gene antitense oligonucleotide improved autonomic impairment associated with TTR amyloidotic autonomic neuropathy (64).
Clinical trials of inotersen and patisiran showed that these agents were able to halt the progression of the disease, with some patients even reducing the burden of polyneuropathy and improving quality of life. The information on their impact on autonomic parameters is limited, warranting further dedicated studies (09).
References
- 01
- Abell TL, Kuo B, Esfandyari T, et al. A randomized, double-blind, placebo-controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis. Neurogastroenterol Motil 2023;35(4);e14523. PMID 36624727
- 02
- Brody F, Vaziri K, Saddler A, et al. Gastric electrical stimulation of gastroparesis. J Am Coll Surg 2008;207(4):533-8. PMID 18926455
- 03
- Burke SM, Avstrikova M, Noviello CM, et al. Structural mechanisms of α7 nicotinic receptor allosteric modulation and activation. Cell 2024;187(5):1160-76.e21. PMID 38382524
- 04
- Byun JI, Kim DY, Moon J, et al. Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension. Ann Clin Transl Neurol 2020;7(1):112-20. PMID 31856425
- 05
- Camilleri M. Advances in diabetic gastroparesis. Rev Gastroenterol Disord 2002;2(2):47-56. PMID 12122960
- 06
- Chelimsky G, Wszolek Z, Chelimsky TC. Gastrointestinal dysfunction in autonomic neuropathy. Semin Neurol 1996;16:259-68. PMID 9085476
- 07
- Chobanian AV, Volicer L, Tifft CP, Gavras H, Liang CS, Faxon D. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med 1979;301:68-73. PMID 449947
- 08
- Coffin ST, Black BK, Biaggioni I, et al. Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Heart Rhythm 2012;9(9):1484-90. PMID 22561596
- 09
- Conceicao I. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system. Clin Auton Res 2019;29(Suppl 1):11-7. PMID 31399774
- 10
- Davies IB, Bannister RG, Sever PS, Wilcox CS. Fludrocortisone in the treatment of postural hypotension: altered sensitivity to pressor agents [proceedings]. Br J Clin Pharmacol 1978;6(5):444P-5P. PMID 728295
- 11
- Kastritis E, Palladini G, Dimopoulos MA, et al. Efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: A phase 2 study by the European Myeloma Network. Blood 2022;140(Suppl 1):7294-6.
- 12
- Ejskjaer N, Wo JM, Esfandyari T, et al. A phase 2a, randomized, double-blind study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25(2):e140-50. PMID 23279217
- 13
- Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med 1995;99:604-10. PMID 7503082
- 14
- Fowler CJ. Neurological disorders of micturition and their treatment. Brain 1999;122(Pt 7):1213-31. PMID 10388789
- 15
- Freeman R. Midodrine and other pressor drugs. In: Robertson D, Low PA, Polinsky RJ, editors. Primer on the autonomic nervous system. New York: Academic Press, 1996:326-32.
- 16
- Furness JB. Types of neurons in the enteric nervous system. J Auton Nerv Syst 2000;81(1-3):87-96. PMID 10869706
- 17
- Goldstein DS, Holmes C, Sharabi Y, Brentzel S, Eisenhofer G. Plasma levels of catechols and metanephrine in neurogenic orthostatic hypotension. Neurology 2003;60:1327-32. PMID 12707437
- 18
- Goyal RK, Hirano I. The enteric nervous system. N Engl J Med 1996;334:1106-15. PMID 8598871
- 19
- Hickler RB, Thompson GR, Fox LM, Hamlin JT. Successful treatment of orthostatic hypotension with 9-alpha-fluorohydrocortisone. N Engl J Med 1959;261:788-91. PMID 14401690
- 20
- Hoeldtke RD, Bryner KD, Hoeldtke ME, Hobbs G. Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine. Clin Auton Res 2006;16(6):390-5. PMID 17036177
- 21
- Hoeldtke RD, Streeten DH. Treatment of orthostatic hypotension with erythropoietin. N Engl J Med 1993;329(9):611-5. PMID 8341335
- 22
- Horowitz M, O'Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 2002;19(3):177-94. PMID 11918620
- 23
- Isaacson S, Vernino S, Ziemann A, et al. Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension. J Am Soc Hypertens 2016;10:755-62. PMID 27614923
- 24
- Jordan J, Shannon JR, Biaggioni I, Norman R, Black BK, Robertson D. Contrasting actions of pressor agents in severe autonomic failure. Am J Med 1998;105:116-24. PMID 9727818
- 25
- Junqueira DR, Bennett D, Huh SY, Fahrbach K, Neupane B, Betts M. Risk of adverse events associated with domperidone and metoclopramide in gastroparesis: systemic review and meta-analysis. Drugs R D 2023;23(1):1-20. PMID 36749528
- 26
- Kanjwal K, Saeed B, Karabin B, Kanjwal Y, Grubb BP. Use of octreotide in the treatment of refractory orthostatic intolerance. Am J Ther 2012;19(1):7-10. PMID 20535001
- 27
- Khashab MA, Ngamruengphong S, Carr-Locke D, et al. Gastric per-oral endoscopic myotomy for refractory gastroparesis: results from the first multicenter study on endoscopic pyloromyotomy. Gastrointest Endosc 2017;85:123-8. PMID 27354102
- 28
- Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol 1999;84:11N-7N. PMID 10503571
- 29
- Kunze WA, Furness JB. The enteric nervous system and regulation of intestinal motility. Annu Rev Physiol 1999;61:117-42. PMID 10099684
- 30
- Lai CC, Fischer PR, Brands CK, et al. Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with midodrine and beta-blockers. Pacing Clin Electrophysiol 2009;32(2):234-8. PMID 19170913
- 31
- Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996;334(14):873-7. PMID 8596569
- 32
- Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997;277(13):1046-51. PMID 9091692
- 33
- Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol 2009;20(3):352-8. PMID 19207771
- 34
- Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-13. PMID 10853004
- 35
- MacLean AR, Allen BV. Orthostatic hypotension and orthostatic tachycardia. Treatment with the "head-up" bed. JAMA 1940;115:2162-7.
- 36
- Mathias CJ, Fosbraey P, da Costa DF, Thornley A, Bannister R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed) 1986;293(6543):353-4. PMID 3089519
- 37
- McCallum RW, Lin Z, Forster J, Roeser K, Hou Q, Sarosiek I. Gastric electrical stimulation improves outcomes of patients with gastroparesis for up to 10 years. Clin Gastroenterol Hepatol 2011;9(4):314-19.e1. PMID 21185396
- 38
- McClellan KJ, Wiseman LR, Wilde MI. Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging 1998;12(1):76-86. PMID 9467688
- 39
- McKenna D, Beverstein G, Reichelderfer M, Gaumnitz E, Gould J. Gastric electrical stimulation is an effective and safe treatment for medically refractory gastroparesis. Surgery 2008;144(4):566-72. PMID 18847640
- 40
- McTavish D, Goa KL. Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs 1989;38(5):757-77. PMID 2480881
- 41
- Molina-Ramos AI, Gómez-Moyano E, Rodríguez-Capitán J, et al. Myocarditis related to COVID-19 and SARS-CoV-2 vaccination. J Clin Med 2022;11(23):6999. PMID 36498573
- 42
- Okamoto LE, Shibao CA, Gamboa A, et al. Synergistic pressor effect of atomoxetine and pyridostigmine in patients with neurogenic orthostatic hypotension. Hypertension 2019;73(1):235-41. PMID 30571543
- 43
- Omboni S, Smit AA, van Lieshout JJ, Settels JJ, Langewouters GJ, Wieling W. Mechanisms underlying the impairment in orthostatic tolerance after nocturnal recumbency in patients with autonomic failure. Clin Sci (Lond) 2001;101:609-18. PMID 11724647
- 44
- Perera R, Isola L, Kaufmann H. Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res 1995;5:211-3. PMID 8520216
- 45
- Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation 2009;120(9):725-34. PMID 19687359
- 46
- Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation 2005;111(21):2734-40. PMID 15911704
- 47
- Ramirez CE, Okamoto LE, Arnold AC, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 2014;64(6):1235-40. PMID 25185131
- 48
- Rao SS. Constipation: evaluation and treatment. Gastroenterol Clin North Am 2003;32(2):659-83. PMID 12858610
- 49
- Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial Sildenafil Diabetes Study Group. JAMA 1999;281:421-6. PMID 9952201
- 50
- Ross AJ, Ocon AJ, Medow MS, Stewart JM. A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome. Clin Sci (Lond) 2014;126(4):289-96. PMID 23978222
- 51
- Saenz de Tejada IS, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989;320:1025-30. PMID 2927481
- 52
- Sakakibara R, Matsuda S, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T. The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin Auton Res 2003;13:106-8. PMID 12720096
- 53
- Shibao C, Raj SR, Gamboa A, et al. Norepinephrine transporter blockade with atomexetine induces hypertension in patients with impaired autonomic function. Hypertension 2007;50(1);47-53. PMID 17515448
- 54
- Shin A, Camilleri M, Busciglio I, et al. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol 2013;11(11):1453-9. PMID 23639598
- 55
- Singer W, Sandroni P, Opfer-Gehrking T, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63:513-8. PMID 16476804
- 56
- Stackl W, Hasun R, Marberger M. Intracavernous injection of prostaglandin E1 in impotent men. J Urol 1988;140(1):66-8. PMID 3379700
- 57
- Talley NJ. Diabetic gastropathy and prokinetics. Am J Gastroenterol 2003;98:264-71. PMID 12591039
- 58
- van Lieshout JJ, ten Harkel AD, Wieling W. Physical maneuvers for combating orthostatic dizziness in autonomic failure. Lancet 1992;339:897-8. PMID 1348300
- 59
- Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982;2:938. PMID 6126784
- 60
- Wein AJ, Van Arsdalen K, Levin RM. Pharmacologic therapy. In: Krane RJ, Siroky MB, editors. Clinical neuro-urology. Boston: Little, Brown and Company, 1992: 523-57.
- 61
- Williams PA, Nikitina Y, Kedar A, Lahr CJ, Helling TS, Abell TL. Long-term effects of gastric stimulation on gastric electrical physiology. J Gastrointest Surg 2013;17(1):50-5. PMID 22956404
- 62
- Winge K, Rasmussen D, Werdelin LM. Constipation in neurological diseases. J Neurol Neurosurg Psychiatry 2003;74:13-9. PMID 12486259
- 63
- Witherington R. Suction device therapy in the management of erectile impotence. Urol ClinNorth Am 1988;15(1):123-8. PMID 3344556
- 64
- Wixner J, Berk JL, Adams D, et al. Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial. Amyloid 2025;32(1):29-38. PMID 39552152
- 65
- Wo JM, Ejskjaer N, Hellstrom PM, et al. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data. Aliment Pharmacol Ther 2011;33(6):679-88. PMID 21214610
- 66
- Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998;51:120-4. PMID 9674789
- 67
- Zentgraf M, Baccouche M, Junemann KP. Diagnosis and therapy of erectile dysfunction using papaverine and phentolamine. Urol Int 1988;43:65-75. PMID 3291360
- 68
- Zorgniotti AW, LeFleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 1985;133:39-41. PMID 2578067
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Authors
-
Aziz I Shaibani MD
Dr. Shaibani of Baylor College of Medicine has no relevant financial relationships to disclose.
See Profile -
Abdulwahhab M Alhabib MD
Dr. Alhabib of Texas Medical Center in Houston has no relevant financial relationships to disclose.
See Profile
Editor
-
Louis H Weimer MD
Dr. Weimer of Columbia University received a consultant honorarium from Roche and Ovid Therapeutics.
See Profile
Former Authors
- Roy Freeman MD
- Duaa Jabari MD
Patient Profile
- Age range of presentation
-
- 0 month to 65+ years
- Sex preponderance
-
- male=female
- Heredity
-
- heredity may be a factor
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Peripheral Neuropathies
Toxic peripheral neuropathies
Jun. 11, 2026
-
Peripheral Neuropathies
Organophosphate neuropathy
Jun. 11, 2026
-
Peripheral Neuropathies
Diphtheritic neuropathy
May. 12, 2026
-
Neuromuscular Disorders
Efgartigimod alfa and hyaluronidase-qvfc
Apr. 23, 2026
-
Peripheral Neuropathies
Acrylamide neuropathy
Apr. 09, 2026
-
Infectious Disorders
Whipple disease
Apr. 08, 2026
-
Peripheral Neuropathies
Neurolymphomatosis
Apr. 07, 2026